BrightGene Submits HKEX Prospectus, Aiming for Main‑Board Listing
BrightGene Bio‑Medical Technology Co., Ltd. (SHA: 688166) filed its prospectus with the Stock Exchange of...
Company
Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib
Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced its 2025 third‑quarter earnings today, reporting operating revenue...
JW Therapeutics & Regeneron Sign Expanded TCR‑T Collaboration, Unlocking $50 Million in Funding
JW Therapeutics Ltd. (HKG: 2126) announced today the signing of a supplementary strategic cooperation agreement...
Novo Nordisk Launches $9 Billion Unsolicited Bid for Metsera, Triggering Battle with Pfizer
Novo Nordisk A/S (NYSE: NVO) announced today an unsolicited offer of USD 9 billion for Metsera, Inc....
Thermo Fisher Secures $8.875B Clario Acquisition, Enhancing Digital‑Trial Endpoint Suite
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a definitive agreement to acquire Clario Holdings, Inc., a...
ModeX Therapeutics Locks $1 B+ Collaboration With Regeneron on Multispecific Antibody Technology
ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK) announced a milestone license and collaboration...
Everest Medicines Secures Exclusive Rights to VIS‑101 in Greater China, Potential 2026 Phase 3 Launch
Hong Kong‑listed Everest Medicines Limited (HKG: 1952) today announced a strategic agreement with Visara, Inc.,...
Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS
Bayer (ETR: BAYN) announced that the U.S. Food and Drug Administration had granted marketing approval...
Ascletis Launches ASC36, a Once‑Monthly Injectable Targeting Obesity
China‑based Ascletis Pharma Inc. (HKG: 1672) announced the selection of ASC36, a once‑monthly subcutaneous injectable...
Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200 M Deal
China‑based Pharmaron Beijing Co., Ltd. (HKG: 3759) announced on October 28, 2025 that it will acquire an...
Sihuan Pharmaceutical Partners with Abalone Bio to Accelerate Obesity Therapeutics Development
China‑based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) and U.S. biotech firm Abalone Bio signed...
Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to €260 Million
Bayer AG (ETR: BAYN) announced that it has entered into a Share Purchase Agreement (SPA)...
Lepu Biopharma Secures Conditional NMPA Approval for Becotatug Vedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma
Lepu Biopharma Co., Ltd. (HKG: 2157) today announced that its antibody‑drug conjugate (ADC) Becotatug Vedotin (MGR003)...
Eli Lilly and NVIDIA Forge Record‑Breaking AI‑Powered Supercomputer for Pharma
Eli Lilly & Co. (NYSE: LLY) today announced a groundbreaking partnership with NVIDIA to build...
Shanghai Ark Biopharma Launches Phase II Trial of AK0610, a Next‑Generation RSV Prophylactic Antibody
Shanghai Ark Biopharmaceutical Co., Ltd. (ARK) today announced the official start of a Phase II clinical...
NovaBridge Biosciences Completes Rebranding, Launches New NBP Ticker on NASDAQ
NovaBridge Biosciences (formerly I‑Mab, NASDAQ: IMAB) announced today that its corporate name change is now...
InnoCare Announces First Patient Dosing of ICP‑B794, a Novel B7‑H3 Targeting ADC
China‑based InnoCare Pharma Limited (SHA: 688428, HKG: 9969) today disclosed that its self‑developed antibody‑drug conjugate...
BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced during its third‑quarter earnings call that it no longer...
GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth
UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) delivered a compelling Q3 2025 earnings report that...
Sihuan Pharmaceutical Secures Fast‑Track Designation for NG‑350A in U.S. Rectal Cancer Treatment
Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that NG‑350A, a clinical‑stage oncolytic immunotherapy...